Mirum Pharmaceuticals, Inc. - 8-K Filing
Mirum Pharmaceuticals issued $690 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, including a $90 million option exercised by initial purchasers. The company plans to use approximately $475 million in net proceeds for the cash portion of note exchange transactions and expects to issue about 3.2 million shares of common stock as part of these exchanges. An additional up to ~6.5 million shares may be issued upon conversion of the notes. (Items: 1.01 Entry Into a Material Definitive Agreement, 2.03 Creation of a Direct Financial Obligation or an Off-Balance Sheet Arrangement, 3.02 Unregistered Sales of Equity Securities, 8.01 Other Events)
Tickers: $MIRM